Classic Mediterranean Kaposi’s Sarcoma Regression With Sirolimus Treatment

Kaposi sarcoma: A continuing conundrum

“…331,332 Moreover, in renal transplant recipients, it has been shown to inhibit KS progression in addition to its immunosuppressive effects. 333,334 New matrix metalloproteinase-2 inhibitors, such as tetracycline analogues without antibiotic activity and chemically modified tetracycline, 313 green tea flavonoids, 321 IL-12, 320 IL-4 receptoredirected cytotoxin, and cartilage extracts 315 have entered clinical trials for the treatment of KS Endothelin-1 receptors, 323 KSHV G-proteinecoupled receptors and angiopoietin-2 may serve as therapeutic targets.…”

Remission eines iatrogenen Kaposi-Sarkoms bei Myasthenia gravis nach Umstellung der Immunsuppression auf den mTOR-Inhibitor Everolimus

“…In einem anderen Fall konnte ein klassisches KS erfolgreich mit Sirolimus behandelt werden [10]. Wir stellen hier einen weiteren Patienten vor, bei dem sowohl die Grunderkrankung als auch das KS durch die Umstellung der immunsuppressiven Therapie auf einen mTORInhibitor kontrolliert werden konnten.…”

Target therapy in gastrointestinal tract sarcoma: What is new?

“…Several recent stud ies have demonstrated that, in patients undergoing a kid neytransplant, the shift from cyclosporine and mycophe nolate mofetil to the mTORinhibitor Sirolimus prevents the progression of Kaposi's sarcoma, also providing an ef fective immunosuppression. Today we know that this drug is an efficient therapy not only for transplant recipients with (iatrogenic) Kaposi's sarcoma [31,32] but also for patients with the classic form of the disease [33,34] . Unfortunately, the immunosuppressive action of Sirolimus makes its use in the treatment of AIDS associated kaposi's sarcoma chal lenging: antiretroviral therapy in combination with chemo therapy (liposomal doxorubicin 6 cycles 20 mg/m 2 iv every 2 wk) is the first choice treatment in these patients.…”